COA ↓

Product

COA Doc

SYN-2619

99.0% Purity SYN-2619 Research Grade HPLC Verified

KLOW 80mg

Quad-Peptide Recovery Complex · Research Grade

Select Strength — 80mg

$180.00

GHK-Cu C₁₄H₂₃CuN₆O₄ · KPV C₁₃H₂₅N₃O₄ · BPC-157 C₆₂H₉₈N₁₆O₂₂ · TB-500 C₂₁₂H₃₅₀N₅₆O₇₈S MW: 403.91 / 287.36 / 1419.56 / 4963.44 g/mol CAS: 89030-95-5 / 79561-22-1 / 137525-51-0 / 77591-33-4

Available on Backorder

Backordered — orders ship within 5–10 business days in the sequence received.

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.0%

HPLC Purity

Lot Number SYN-2619-KLOW

Test Date March 2026

Labeled 80 mg

Actual 80.1 mg

99.3%

HPLC Purity

Lot Number SYN-2518-KLOW

Test Date June 2026

Labeled 80 mg

Actual 80.2 mg

Research Data

KEY FINDINGS

🧬

Synergistic Peptide Pathways

GHK-Cu + KPV + BPC-157 + TB-500 — four complementary repair mechanisms

🔬

4,000+

Genes Modulated (GHK-Cu)

GHK-Cu alone modulates 4,000+ human genes across collagen and repair pathways

✅

99.0%

HPLC-Verified Purity

Current batch SYN-2619, third-party accredited lab — all 4 components

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🧬 KPV — NF-κB Pathway

Alpha-MSH-Derived KPV — Upstream Anti-Inflammatory

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH, an endogenous anti-inflammatory neuropeptide. KPV inhibits NF-κB activation and downstream cytokine production in colonic epithelial and immune cell models — with particular efficacy in gut inflammation research (IBD models).

🔬 KPV inhibits NF-κB by 58% — providing upstream anti-inflammatory control complementary to BPC-157's localised repair mechanism.

PMID 14985361 — J. Immunol.

🔬 Synergistic Pathway Coverage

KLOW — Four Complementary Repair Mechanisms

The KLOW formulation combines GHK-Cu (gene modulation, collagen synthesis), KPV (NF-κB anti-inflammatory), BPC-157 (VEGF, FAK-paxillin localised repair), and TB-500 (actin sequestration, systemic wound healing) — providing full-spectrum coverage from upstream inflammation control to systemic tissue regeneration.

🔬 Four peptides, four complementary mechanisms — the most comprehensive single-vial recovery formulation in the Syntra catalogue.

PMID 14985361 — J. Immunol.

4 Pathways

Full-Spectrum Recovery Complex — 4 Synergistic Mechanisms

KLOW combines four research peptides targeting the complete recovery pathway: GHK-Cu for gene modulation and collagen synthesis; KPV for upstream NF-κB anti-inflammatory signalling; BPC-157 for localised tissue repair via VEGF and FAK-paxillin; TB-500 for systemic actin-mediated healing.

Pathway Coverage — KLOW Components vs. Individual Peptides

Anti-inflammatory (KPV — NF-κB) MC1R + NF-κB

Local repair (BPC-157 — VEGF) FAK-Paxillin

Systemic healing (TB-500) Actin binding

Gene modulation (GHK-Cu) 4,000+ genes

Syntra Research Formulation Analysis — Component pathway data

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2619-KLOW

Specification	Value
CAS Number	89030-95-5 / 79561-22-1 / 137525-51-0 / 77591-33-4
Molecular Formula	GHK-Cu C₁₄H₂₃CuN₆O₄ · KPV C₁₃H₂₅N₃O₄ · BPC-157 C₆₂H₉₈N₁₆O₂₂ · TB-500 C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight	403.91 / 287.36 / 1419.56 / 4963.44 g/mol
Purity (HPLC)	99.0%
Appearance	White/light blue lyophilised powder
Solubility	Soluble in water (1 mg/mL per component)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

4 ×

Synergistic Repair Pathways — Full-Spectrum Coverage vs. Single-Peptide Protocols

GHK-Cu (collagen synthesis) +70%

BPC-157 (wound healing) 3.2×

TB-500 (systemic repair) 2.8×

KPV (NF-κB inhibition) −58%

Comparative Activity Profile

KLOW (Stack) BPC-157 alone

Observed Adverse Indicators

Cytotoxicity (any component)

None

Component antagonism

None

Combined angiogenic activity

Expected

NF-κB pathway inhibition

Expected

⚠️ Theoretical Concern

Combined Angiogenic Activity — Additive Effect

Both BPC-157 (VEGF pathway) and TB-500 (eNOS/SDF-1) promote angiogenesis through independent mechanisms. Combined, this angiogenic activity is additive. Researchers using angiogenesis-sensitive models should account for this combined effect.

No cytotoxicity for any of the four components in published in vitro studies at research concentrations
GHK-Cu, BPC-157, and TB-500 have independent comprehensive safety data — KPV has established anti-inflammatory safety profile
Combined angiogenic promotion (BPC-157 + TB-500) is consistent with intended wound-healing research applications

KLOW 80mg

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

Alpha-MSH-Derived KPV — Upstream Anti-Inflammatory

KLOW — Four Complementary Repair Mechanisms

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Combined Angiogenic Activity — Additive Effect

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS